BEIJING, January 20, 2026 – Co-administration of SINOVAC’s live attenuated varicella vaccine (VarV) and trivalent inactivated influenza vaccine (Anflu®) was shown to be safe and immunogenic in in heal
BEIJING, Jan. 4, 2026 — SINOVAC Biotech Ltd. ("SINOVAC" or the "Company"), a leading global provider of biopharmaceutical products, has been awarded an exclusive contract under the
BEIJING, Jan. 7, 2026 – On January 6, 2026, Sinovac Life Sciences Co., Ltd., a subsidiary of Sinovac Biotech Ltd. (“SINOVAC” or the “Company”), initiated the enrollment of volunteer subjects for a Pha
BEIJING--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today provided an update on the Antigua High Co
BEIJING -- Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced that the Antigua High Court has ordered that the dire